北京协和医院林国乐教授于国际期刊颁布论文:ctDNA可精细预测直肠癌围手术期治疗疗效和预后
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">近期</span>,北京协和医院外科林国乐教授联合全国多家医疗中心,前瞻性观察了ctDNA在肠癌<span style="color: black;">病人</span>新辅助治疗前后的水平变化,证实ctDNA可预测肠癌新辅助治疗(nCRT)疗效,ctDNA检出及丰度是预测肠癌<span style="color: black;">病人</span><span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>(MFS)的<span style="color: black;">靠谱</span>指标。<span style="color: black;">文案</span>在线<span style="color: black;">发布</span>于Clinical Cancer Research。</p>
<div style="color: black; text-align: left; margin-bottom: 10px;"><img src="https://pic4.zhimg.com/80/v2-343256f11edc8d4814e28f1f8b91492b_720w.webp" style="width: 50%; margin-bottom: 20px;"></div>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">该<span style="color: black;">科研</span>成果基于1021基因Panel的高深度测序,首次证实了ctDNA可在nCRT治疗前预测短期和中期远处转移,为肠癌<span style="color: black;">病人</span>新辅助治疗获益人群的筛选和复发转移的预测<span style="color: black;">供给</span>了更加<span style="color: black;">精细</span>的<span style="color: black;">办法</span>。</p>
<h2 style="color: black; text-align: left; margin-bottom: 10px;"><span style="color: black;">科研</span>结果</h2>
<h2 style="color: black; text-align: left; margin-bottom: 10px;">1 ctDNA 可预测肠癌nCRT的疗效</h2>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">科研</span>分别在nCRT前、nCRT治疗过程中、手术前、手术后对<span style="color: black;">病人</span>进行ctDNA检测,其中基线ctDNA阳性率为75%,随着治疗的深入,快速下降到nCRT治疗时的15.5%、术前的10.5%和术后的6.7%,提示ctDNA可准确反应肿瘤负荷。更<span style="color: black;">要紧</span>的是,术前未检测到ctDNA阳性的29位<span style="color: black;">病人</span>均达到病理缓解(ypCR),病理评级为ypCAP0-1、ypCR、ypT0-2和mrEMVI(-)的<span style="color: black;">病人</span>中,术前ctDNA的阳性率<span style="color: black;">显著</span>较低,<span style="color: black;">显示</span>ctDNA能够预测肠癌nCRT的疗效。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">另外</span>,数据分析<span style="color: black;">发掘</span>,基线ctDNA 与mrEMVI<span style="color: black;">明显</span><span style="color: black;">关联</span>,术前ctDNA与ymrEMVI<span style="color: black;">关联</span>,<span style="color: black;">因为</span>mrEMVI与ymrEMVI是<span style="color: black;">没</span>转移<span style="color: black;">存活</span>的<span style="color: black;">重要</span>预测指标,ctDNA与二者的关系可能<span style="color: black;">拥有</span>潜在的临床<span style="color: black;">指点</span>价值,<span style="color: black;">必须</span>进一步<span style="color: black;">科研</span>。</p>
<h2 style="color: black; text-align: left; margin-bottom: 10px;">2 POLD1等基因突变状态与nCRT 疗效<span style="color: black;">关联</span></h2>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">POLD1以及POLE突变多次被<span style="color: black;">报告</span>与免疫治疗超<span style="color: black;">发展</span><span style="color: black;">相关</span>,在本<span style="color: black;">科研</span>中,<span style="color: black;">发掘</span>POLD1、FAT2和ZFHX3突变的<span style="color: black;">病人</span>,病理缓解<span style="color: black;">情况</span>更好,其中8位携带POLD1突变<span style="color: black;">病人</span>中,6位达到ypCR,2位达到ypCAP1。<span style="color: black;">另外</span>,携带POLD1突变<span style="color: black;">病人</span>的肿瘤突变负荷(TMB)较高,并且ypCAP 0-1亚组的TMB要比ypCAP 2-3亚组高,<span style="color: black;">显示</span>POLD1突变及TMB-H可能是预测nCRT疗效的潜在指标。</p>
<div style="color: black; text-align: left; margin-bottom: 10px;"><img src="https://pic1.zhimg.com/80/v2-47a935c0adaf0d3305411db2c4706da8_720w.webp" style="width: 50%; margin-bottom: 20px;"></div>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">(<span style="color: black;">照片</span><span style="color: black;">源自</span>于英文原文)</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">POLD1突变及TMB-H可能是预测nCRT疗效的潜在指标</p>
<h2 style="color: black; text-align: left; margin-bottom: 10px;">3 ctDNA预测复发转移更为<span style="color: black;">靠谱</span></h2>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">科研</span>对入组<span style="color: black;">病人</span>进行了中位18个月的随访,以观察ctDNA及其他临床指标<span style="color: black;">针对</span>复发转移的预测价值。截止发稿前,共有13位<span style="color: black;">病人</span>(12.5%)<span style="color: black;">出现</span>了远处转移。分析<span style="color: black;">发掘</span>,所有时间节点检测中,ctDNA阳性<span style="color: black;">病人</span>比阴性<span style="color: black;">病人</span>更快<span style="color: black;">出现</span>远处转移,<span style="color: black;">危害</span><span style="color: black;">亦</span>随着时间呈现<span style="color: black;">逐步</span><span style="color: black;">增多</span>的趋势。</p>
<div style="color: black; text-align: left; margin-bottom: 10px;"><img src="https://pic1.zhimg.com/80/v2-be9dcffd4a23d38f276736f5be63974c_720w.webp" style="width: 50%; margin-bottom: 20px;"></div>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">(<span style="color: black;">照片</span><span style="color: black;">源自</span>于英文原文)各节点的ctDNA含量均与远处转移<span style="color: black;">显著</span><span style="color: black;">关联</span></p>
<div style="color: black; text-align: left; margin-bottom: 10px;"><img src="https://pic1.zhimg.com/80/v2-179d25c03b5f37d97c4fbc11ea89c68c_720w.webp" style="width: 50%; margin-bottom: 20px;"></div>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">(<span style="color: black;">照片</span><span style="color: black;">源自</span>于英文原文)ctDNA阳性预测远处转移更<span style="color: black;">靠谱</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">各时间节点ctDNA的含量<span style="color: black;">亦</span>与远处转移<span style="color: black;">拥有</span><span style="color: black;">关联</span>性,其中基线ctDNA>1% 的中位VAF<span style="color: black;">针对</span>初始治疗前的<span style="color: black;">初期</span>转移预测价值<span style="color: black;">显著</span>。<span style="color: black;">另外</span>,<span style="color: black;">科研</span><span style="color: black;">发掘</span>在血清标志物(CEA,CA19-9)阴性的<span style="color: black;">病人</span>中,<span style="color: black;">亦</span><span style="color: black;">能够</span>检出ctDNA,并且不同的ctDNA丰度<span style="color: black;">能够</span>提示预后。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">林国乐教授团队<span style="color: black;">科研</span>成果基于1021基因Panel的高深度测序,首次证实了ctDNA可在nCRT治疗前预测短期和中期远处转移,为肠癌<span style="color: black;">病人</span>新辅助治疗获益人群的筛选和复发转移的预测<span style="color: black;">供给</span>了更加<span style="color: black;">精细</span>的<span style="color: black;">办法</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">随着检测技术的<span style="color: black;">加强</span>,ctDNA 已<span style="color: black;">逐步</span>克服在<span style="color: black;">初期</span>肿瘤临床应用的局限,良好的<span style="color: black;">敏锐</span>性<span style="color: black;">针对</span>肿瘤复发转移的预测越来越<span style="color: black;">精细</span>。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">参考文献</p>Zhou J, Wang C, Lin G, et al. Serial circulating tumor DNA in predicting and monitoring the effect of neoadjuvant chemoradiotherapy in patients with rectal cancer: a prospective multicenter study. Clin Cancer Res. 2020 Oct 12:clincanres.2299.2020. doi: 10.1158/1078-0432.CCR-20-2299<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">专家简介</p>
<div style="color: black; text-align: left; margin-bottom: 10px;"><img src="https://pic1.zhimg.com/80/v2-538ba942949bbeb9c281d522682650bc_720w.webp" style="width: 50%; margin-bottom: 20px;"></div>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">林国乐</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">北京协和医院基本外科结直肠专业组<span style="color: black;">专家</span>医师</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">教授,博士<span style="color: black;">科研</span>生导师</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">兼任中华医学会外科学分会胃肠外科学组委员</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">中国抗癌协会大肠癌专业委员会常务委员及TEM学组副组长</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">中国医师协会外科医师分会肛肠外科医师委员会委员、结直肠外科医师委员会中青年副<span style="color: black;">专家</span>委员</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">北京癌症防治学会直肠癌新辅助治疗专业委员会<span style="color: black;">专家</span>委员</p>(本文<span style="color: black;">源自</span>:《肿瘤瞭望》编辑部)
软文发布平台 http://www.fok120.com/ 这篇文章真的让我受益匪浅,外链发布感谢分享! 期待你更多的精彩评论,一起交流学习。 外贸网站建设方法 http://www.fok120.com/ 论坛是一个舞台,让我们在这里尽情的释放自己。 你的话深深触动了我,仿佛说出了我心里的声音。
页:
[1]